D PP (dipeptidyl peptidase)-4 inhibitors are widely used in the treatment of type 2 diabetes mellitus (T2DM). DPP4 is a transmembrane serine protease that selectively cleaves the amino-terminal dipeptide from peptides with an amino-terminal penultimate proline or alanine, including the incretin hormones GLP-1 (glucagon-like peptide-1) and glucose-dependent insulinotropic peptide.
D PP (dipeptidyl peptidase)-4 inhibitors are widely used in the treatment of type 2 diabetes mellitus (T2DM). DPP4 is a transmembrane serine protease that selectively cleaves the amino-terminal dipeptide from peptides with an amino-terminal penultimate proline or alanine, including the incretin hormones GLP-1 (glucagon-like peptide-1) and glucose-dependent insulinotropic peptide.
1 DPP4 inhibitors improve glucose homeostasis by increasing incretins after ingestion of a meal, increasing postprandial insulin secretion, decreasing glucagon release, delaying gastric emptying, and reducing appetite. 2 In addition to decreasing the degradation of GLP-1 and glucose-dependent insulinotropic peptide, DPP4 inhibitors prevent the degradation of several vasoactive peptides, including brain natriuretic peptide, substance P, and NPY (neuropeptide Y). Indeed, the kcat/Km constant of DPP4 for NPY (1-36; hereafter referred to as NPY) is 36-and 73-fold higher than the kcat/Km for GLP-1 and glucose-dependent insulinotropic peptide, respectively.
1 NPY is coreleased with norepinephrine during sympathetic activation, causes vasoconstriction via Y1 receptors, and potentiates the action of norepinephrine at the α-adrenergic receptor. The NPY metabolite, NPY , formed from DPP4, is inactive against the Y1 receptor and activates Y2 and Y5 receptors. 3 Stimulation of presynaptic Y2 receptors decreases the release of norepinephrine. Thus, inhibiting the cleavage of NPY to NPY (3-36) by DPP4 could enhance vasoconstrictor effects of NPY.
Studies in rodents suggest that decreased degradation of NPY contributes to cardiovascular effects of DPP4 inhibitors. For example, DPP4 inhibition increases blood pressure (BP) in rats that have been pretreated with the angiotensin-converting enzyme (ACE) inhibitor captopril and this effect is blocked by administration of a Y1 receptor antagonist. 4 DPP4 inhibition potentiates the vasoconstrictor response to NPY and Ang II (angiotensin II) in spontaneously hypertensive rats.
5 DPP4 inhibition promotes proliferation and collagen formation by cardiac fibroblasts by NPY through a Y1 receptor-dependent mechanism. 6 Whether DPP4 inhibitors potentiate the effects of NPY in humans is not known. As in rodent models, DPP4 inhibition attenuates the antihypertensive response to acute ACE inhibition in subjects with the metabolic syndrome. 7 In addition, combined inhibition of DPP4 and ACE activates the sympathetic nervous system, and potentiates stimulation of norepinephrine release by substance P, a substrate common to DPP4 and ACE. 7, 8 Increased sympathetic activation could result in higher endogenous NPY concentrations. In addition, the vasodilator peptide bradykinin is also a substrate of ACE and could modulate vasoconstriction, highlighting the potential for complex interactive effects of ACE, and DPP4 inhibition on the vasculature.
Understanding the effect of DPP4 inhibition on NPYmediated vasoconstriction has important clinical implications. NPY concentrations are increased in patients with heart failure. 9 Some retrospective studies and 2 randomized clinical trials have suggested that DPP4 inhibitor treatment is associated with an increased risk of heart failure. In SAVOR-TIMI (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis In Myocardial Infarction) 53, treatment with saxagliptin was associated with a significantly increased risk of hospitalization for heart failure compared with placebo in patients with T2DM who had a history of or were at risk for cardiovascular events. 10 In a post hoc analysis of the EXAMINE trial (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care), there was no significant effect of alogliptin on the risk of heart failure in all patients studied, but the risk of hospitalization for heart failure was significantly increased in alogliptin-treated patients who had no history of heart failure before the study. 11 The present study tested the hypothesis that DPP4 inhibition with sitagliptin potentiates the forearm vasoconstrictor response to brachial artery infusion of NPY in healthy volunteers or individuals with T2DM. We tested this hypothesis in the absence and presence of concurrent ACE inhibition by intra-arterial infusion of enalaprilat. Last, because any combined effect of DPP4 and ACE inhibition on the vasoconstrictor response to NPY could result from decreased degradation of shared substrates or from an interaction between the vasoconstrictor effects of NPY and Ang II, we also examined the effect of sitagliptin versus placebo on the vasoconstrictor response to NPY during concurrent treatment with the angiotensin receptor blocker (ARB) valsartan.
Methods
Data will be made available to investigators on request.
Study Subjects
Eighteen nonsmokers (12 healthy controls and 6 with T2DM), 18 to 55 years of age, participated in 1 of 2 randomized, double-blinded, placebo-controlled crossover protocols. The study was approved by the Vanderbilt University Institutional Review Board, and all subjects provided informed written consent before initiation of study procedures. Patients were excluded if they had a history of hypertension (systolic BP >140 mm Hg or diastolic BP >90 mm Hg or treatment with antihypertensive medication), cardiovascular disease, or chronic renal or hepatic disease. Subjects were defined as having diabetes mellitus by fasting blood sugar of ≥126 mg/dL, hemoglobin A1c ≥6.5, or a blood sugar ≥200 mg/dL after oral ingestion of 75 g of glucose. Diabetic subjects were excluded if they had poorly controlled diabetes mellitus (hemoglobin A1c >8.7%), T1DM, or were using any antidiabetic medications other than metformin. β-hCG (beta-human chorionic gonadotropin) testing was performed in women of childbearing age to exclude pregnancy.
Protocol 1
Each subject underwent 2 study days separated by 5 weeks ( Figure S1 in the online-only Data Supplement). Before the first study day, subjects were randomized to order of treatment with sitagliptin 100 mg/d and matching placebo for 7 days. Subjects were randomized using a permuted block method. The Vanderbilt Investigational Drug Service recorded subject assignments and dispensed study drug in blinded fashion. On the last day of the first treatment, subjects reported to the Vanderbilt Clinical Research Center in the fasting state. Subjects were studied in the supine position in a temperature controlled room. After each subject received his or her last dose of study medication, a catheter was placed in the antecubital vein of the nondominant arm for blood sampling and a brachial arterial line was inserted adjacent to the IV for arterial blood sampling and drug administration. BP and heart rate (HR) were monitored throughout the study using the VITAL-GUARD 450c monitor (Ivy Biomedical Systems, Branford, CT). After a 30-minute rest period, we measured spectral analysis of HR and BP variability as previously described. 12 The following autonomic measurements were obtained: sympathetic activity (lowfrequency variability of BP [LF SBP ], plasma norepinephrine), parasympathetic activity (high-frequency variability of HR [HF RRI ]), and spontaneous baroreflex sensitivity. BP was monitored continuously with finger arterial pressure contour analysis (NEXFIN, BMEYE, Amsterdam, The Netherlands). Data were obtained although the patient was resting in the supine position, in a quiet environment for at least 10 minutes. Data were acquired using the Windaq data acquisition system (DI-720, DATAQ Instruments, Akron, OH) and analyzed off-line with custom software written in the PV Wave (Visual Numerics, Houston, TX) and MATLAB (Mathworks, Natick, MA) environments.
Venous blood was drawn for measurement of DPP4 activity, ACE activity, glucose, insulin, and GLP-1. NPY (Clinalfa Basic, Bachem, Germany) was then infused at 0.1, 0.3, 1.0, and 3.0 nmol/min for 10 minutes at each dose. The doses were chosen based on previously published forearm vasoconstrictor response to NPY. 13 Infusion of normal saline was adjusted to maintain the total infusion volume of 1 mL/min.
At baseline and at the end of each dose, forearm blood flow (FBF) was measured using mercury-in-silastic strain gauge plethysmography. (See online-only Data Supplement for information on study procedures and laboratory analysis.) Spectral analysis of HR and BP variability was also repeated after the last dose. Simultaneous venous and arterial blood samples were obtained after FBF measurement and power spectral analysis at baseline and at the end of each dose of NPY for norepinephrine and NPY. After the last dose of NPY, there was a 90-minute washout period before enalaprilat was administered through the arterial line at 0.33 μg/ min per 100 mL forearm volume. Twenty minutes later, spectral analysis of HR and BP variability was repeated. A second infusion of NPY at graded doses was started 10 minutes after that. As before, FBF measurements and blood sampling were performed at the end of each dose of NPY, and spectral analysis of HR and BP variability was performed after the last dose. The study protocol was repeated on the second study day after 4-week washout and 7-day treatment with the opposite study drug.
Protocol 2
During Protocol 2, each participant was again randomized to order of treatment with sitagliptin 100 mg/d and matching placebo for 7 days but was also given valsartan 160 mg/d for 7 days during both treatment periods ( Figure S2 ). At the end of each treatment period, subjects reported to the Clinical Research Center in the fasting state. The study day protocol was identical to that used in Protocol 1, except that NPY was infused in graded doses only once and no intra-arterial enalaprilat was administered.
Statistical Analysis
Descriptive statistics are provided as the mean±SD for continuous variables and frequencies for categorical variables. We originally designed the study with a sample size of 18 to provide a power of 93% to detect a 10-fold shift to the left in the dose-response curve and of 61% to detect a 3-fold shift to the left during sitagliptin, based on previously published data. 13 Because there was only enough NPY commercially available to study a total of 18 subjects, and our original power was high, a recalculation of the power showed that a sample size of 13 provided a power of 81% to detect a 10-fold shift to the left in the dose-response curve. This change still enabled us to study 5 subjects during valsartan. Comparisons between baseline values in healthy versus diabetic subjects or during sitagliptin versus during placebo were made using the (paired) 2 sample t test. We tested for a carryover effect using the sum of the measurements during sitagliptin and placebo days when NPY=0 for each subject 14 and found no carryover effect between study days. In addition, we tested for a carryover effect of NPY on FBF and forearm vascular resistance (FVR) within each study day by measuring a repeat baseline before initiation of enalaprilat. After an interim analysis showed a carryover effect of NPY on FBF and FVR within each study day, the 3.0 nmol/min dose of NPY was eliminated and the duration of each dose was reduced to 5 minutes in the last 8 subjects studied (3 diabetic subjects in Protocol 1 and all participants in Protocol 2). Because of carryover effect of NPY on FBF and FVR within the study day, we analyzed the effect of sitagliptin versus placebo before enalaprilat and during enalaprilat separately. Mixed-effect models were used to analyze the data with a random subject effect and with treatment factor (sitagliptin versus placebo), categorical NPY dose and the baseline (pre-NPY) measurement as a fixed effect. Statistical analyses were performed using IBM SPSS version 24 and R version 3.3.2 (http://www.r-project.org). Table 1 provides the baseline characteristics of the study participants. Subjects with diabetes mellitus were significantly older than healthy controls. Fasting glucose and hemoglobin A1c were significantly higher in diabetic participants (all treated either with diet alone or metformin) compared with healthy controls.
Results

Subject Characteristics
Effect of Sitagliptin and Enalaprilat on Hemodynamic and Metabolic Parameters
There was no effect of sitagliptin or intra-arterial enalaprilat on baseline BP in either diabetic participants or healthy controls (Table 2) . In healthy controls, baseline HR was significantly higher during intra-arterial enalaprilat compared with during placebo alone. Sitagliptin significantly reduced DPP4 activity and there was no interactive effect of enalaprilat on DPP4 activity. Intra-arterial enalaprilat significantly reduced ACE activity in the presence and absence of sitagliptin. Sitagliptin alone had a small but significant effect on ACE activity in healthy controls. In addition, in the absence of enalaprilat, baseline ACE activity was lower in diabetics compared with healthy controls.
Fasting glucose concentrations were significantly higher in diabetic patients compared with healthy controls during placebo, sitagliptin, and placebo+enalaprilat. Fasting glucose concentrations were significantly decreased during treatment with sitagliptin and enalaprilat compared with during sitagliptin alone in both diabetic and nondiabetic participants. Fasting insulin was also decreased during Results are shown as mean±SD. BMI indicates body mass index. Figure 2 shows the effect of intra-arterial NPY on FBF and FVR in diabetic participants. NPY significantly decreased FBF under all treatment conditions except during enalaprilat+sitagliptin (P<0.005 for all others) and increased FVR (all P<0.03) under all treatment conditions in diabetic subjects. In the absence of enalaprilat, there was no effect of sitagliptin alone on the FBF response to intra-arterial NPY in diabetics, whereas sitagliptin attenuated the increase in FVR in response to NPY (P=0.010). As in healthy controls, during enalaprilat, sitagliptin significantly potentiated both the FBF (P=0.007) and FVR (P=0.003) response to intra-arterial NPY in diabetics.
We also analyzed the effect of sitagliptin on the vasoconstrictor response to NPY (up to the 1 nmol/min dose) in all subjects (healthy controls and those with diabetes mellitus). In this combined group, sitagliptin did not affect the FBF or FVR response to NPY in the absence of ACE inhibition with enalaprilat. During intra-arterial enalaprilat, sitagliptin potentiated the vasoconstrictor response to NPY as measured as FBF (P<0.001) or FVR (P=0.031).
Effect of Treatment on NPY and NPY (3-36) Concentrations
To determine whether decreased degradation of NPY during sitagliptin contributed to enhanced vasoconstriction, we analyzed concentrations of NPY and its metabolite via degradation by DPP4, NPY (3-36), in venous plasma from the infused arm in the diabetic subjects studied. Baseline NPY and NPY (3-36) concentrations were statistically similar during sitagliptin and placebo treatment days in the absence of enalaprilat. During enalaprilat, baseline endogenous NPY was significantly higher during sitagliptin compared with placebo (6.99±6.87 versus 2.38±2.15 pmol/L; P=0.03), whereas NPY (3-36) tended to be lower (4.6±2.3 versus 9.5±7.5 pmol/L; P=0.06). During enalaprilat, the baseline molar ratio of NPY to NPY (3-36) was significantly increased during sitagliptin compared with placebo (1.88±1.82 versus 0.33±0.31; P=0.03).
Intra-arterial infusion of NPY increased NPY and its metabolite NPY (3-36) in a dose-dependent manner ( Figure 3 ). Treatment with sitagliptin tended to increase NPY and decrease NPY (3-36) concentrations, but these effects did not reach significance. The ratio of the Y1 agonist NPY to the Y2 agonist NPY (3-36) was dramatically and significantly increased during infusion of NPY in the presence of sitagliptin, however (Figure 3) . There was no effect of enalaprilat on NPY, NPY or the ratio of the 2.
Effect of Treatment on HR and Net Forearm Norepinephrine Release or Extraction
To determine whether sympathetic activation contributed to enhanced vasoconstriction during sitagliptin and enalaprilat, we analyzed HR and forearm norepinephrine release before and during 1.0 nmol/min intra-arterial NPY under all treatment conditions (Table S1 ). Baseline norepinephrine release was significantly higher during sitagliptin and enalaprilat compared with during placebo (33.3±76.8 versus −58.5±109.3). Although NPY increased norepinephrine release during placebo, however, there was no effect of NPY on norepinephrine release during sitagliptin with or without enalaprilat. There was no effect of any treatment on the low-frequency systolic BP (LF SBP ). The ratio of R-R interval (LF RRI ) to high-frequency RRI (HF RRI ) was increased during sitagliptin+enalaprilat compared with placebo.
Effect of DPP4 Inhibition on the Vasoconstrictor Response to NPY During Treatment With an ARB
The mechanism through which DPP4 inhibition potentiated the vasoconstrictor response to intra-arterial NPY during ACE inhibition could involve decreased degradation of a shared DPP4 and ACE substrate, or could reflect an effect of DPP4 inhibition on NPY-induced vasoconstriction that is unmasked when the renin-angiotensin-aldosterone system is interrupted. To differentiate between these 2, we studied the effect of sitagliptin versus placebo on the vasoconstrictor response to intra-arterial NPY during concurrent administration of the ARB valsartan in 5 healthy controls (Protocol 2; Figure S2 ). Sitagliptin significantly reduced DPP4 activity but did not affect BP, HR, or fasting glucose (Table S2) . NPY infusion significantly decreased FBF and increased FVR under both conditions (all P<0.001; Figure 4) . Compared with placebo, The vasoconstrictor response to NPY observed during sitagliptin and valsartan (FBF, 1.18±0.21 mL/min per 100 mL and FVR, 67.03±14.37 mm Hg/[mL·min·100 mL] at the 1.0 nmol/min NPY dose) was similar to that observed during sitagliptin and enalaprilat (FBF, 1.24±0.41 mL/min per 100 mL and FVR, 67.25±15.51 mm Hg/[mL·min·100 mL] at the 1.0 nmol/min NPY dose).
Discussion
We report for the first time that DPP4 inhibition with sitagliptin potentiates the vasoconstrictor response to NPY in the human forearm. Sitagliptin potentiated NPY-induced vasoconstriction during ACE inhibition in both healthy controls and individuals with diabetes mellitus whereas there was no effect of sitagliptin on FBF in the absence of ACE inhibition in diabetics and a minimal effect in the absence of ACE inhibition in healthy controls. We also report for the first time in humans that sitagliptin decreased the degradation of NPY to NPY (3-36), as reflected by the molar ratio of the 2 during intra-arterial infusion; there was no interactive effect of DPP4 and ACE inhibition on NPY or NPY (3-36) concentrations. In healthy controls, sitagliptin potentiated the vasoconstrictor response to NPY during ARB treatment as well as ACE inhibition. Taken together, these data indicate DPP4 inhibition alters the balance between Y1 agonist NPY and the Y2 agonist NPY (3-36), and this results in enhanced vasoconstriction when the renin-angiotensin system is inhibited.
Studies in vitro and in rodent models have shown that DPP4 inhibitors prevent the degradation of the vasoconstrictor and Y1 agonist, NPY. 15, 16 The observation that sitagliptin potentiates the vasoconstrictor response to NPY during ACE inhibition is consistent with prior studies in rodents, as well as 1 prior study in humans showing an interactive effect of DPP4 and ACE inhibition on BP. 7, 17 The finding that ACE inhibition did not alter the effect of sitagliptin on the NPY to NPY (3-36) ratio suggests a pharmacodynamic rather than a pharmacokinetic interaction with DPP4 inhibition. Potentiation of the vasoconstrictor response to NPY by sitagliptin during valsartan, as well as enalaprilat also supports a pharmacodynamic interaction. The direction of this interactive effect may seem paradoxical. In rodents, NPY enhances vasoconstriction in response to exogenous Ang II via a Y1 receptor-dependent mechanism and inhibition of the degradation of NPY to NPY (3-36) by DPP4 enhances this effect. 5 Drugs that decrease Ang II production or diminish AT 1 receptor activation might therefore be expected to diminish vasoconstriction in response to NPY. However, ACE inhibitors and AT 1 receptor blockers have been reported to reduce sympathetic activation and peripheral endogenous immunoreactive NPY concentrations, and upregulate the Y1 receptor, 18, 19 but the identity of the NPY peptide decreased (ie, NPY or NPY ) is unknown, as commonly used immunoassays do not distinguish between NPY and its metabolites. We did not detect an effect of enalaprilat or valsartan on sympathetic activation during NPY infusion. Rather, we hypothesize that decreasing the formation or action of Ang II unmasks an enhanced vasoconstrictor response to exogenous NPY when degradation to NPY (3-36) is inhibited by sitagliptin.
This study has important clinical implications. Immunoreactive NPY and norepinephrine concentrations are increased in patients with heart failure and higher levels have been associated with poor outcomes. 9, 20, 21 When systemic NPY concentrations are increased in heart failure patients taking an ACE inhibitor or ARB and DPP4 inhibitor, enhanced vasoconstriction could result in increased afterload and left ventricular end-diastolic pressure. Three large randomized clinical trials examined the cardiovascular safety of DPP4 inhibition in high-risk patients. In the SAVOR-TIMI 53 trial, treatment with saxagliptin was associated with a significantly increased risk of hospitalization for heart failure compared with placebo in patients with T2DM who had a history of or were at risk for cardiovascular events. 10 In a post hoc analysis of the EXAMINE trial alogliptin increased the risk of hospitalization for heart failure in patients without a prior history of heart failure. 22 A large proportion of patients who take a DPP4 inhibitor also take an ACE inhibitor or ARB. Fifty-four percent of patients in SAVOR-TIMI 53 were taking an ACE inhibitor, and 28% were taking an ARB. 10 There was no difference in risk between ACE/ARB and non-ACE/ARB users but there was a trend (P=0.06) toward a significant effect of saxagliptin in non-β blocker users versus β-blocker users, consistent with a sympathetically mediated effect of DPP4 inhibition on risk of heart failure. 10 Eighty-two percent of patients in EXAMINE were taking a renin-angiotensin system blocking drug. 22 In a post hoc analysis, White et al 23 found no relationship between concurrent ACE inhibitor use and cardiovascular outcomes in alogliptin-treated patients. However, alogliptin reduced systolic BP in non-ACE inhibitor users but not in ACE inhibitor users. We studied the effect of sitagliptin. Of note, the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) did not detect an increased risk of heart failure in patients with T2DM and cardiovascular disease in patients randomized to sitagliptin versus placebo. 24 This could challenge the concept that increased risk of hospitalization for heart failure is a class effect of DPP4 inhibitors, but differences in study design may account for this observation. In TECOS, the use of open-label antidiabetic agents was encouraged to achieve hemoglobin A1c targets to minimize any confounding difference in glucose control between study arms. As a consequence, patients in the placebo arm were significantly more likely to have had initiated additional antidiabetic agents, which could have confounded cardiovascular outcomes. The use of antidiabetic agents was similar in the placebo and alogliptin arms of EXAMINE; metformin, sulfonylurea, and thiazolidinedione use was similar in placebo and saxagliptin arms of SAVOR-TIMI 53. 10, 25 In addition, sitagliptin has been associated with an increased risk of hospitalization for heart failure in a population-based retrospective cohort study. 26 As in rodent models, the cardiovascular effects of DPP4 inhibition in humans are likely context dependent. DPP4 inhibition increased BP in spontaneously hypertensive rats, but sitagliptin lowered BP in rats with the metabolic syndrome. 17 This effect was because of differences in the renovascular response to peptides like NPY. In humans, the effect of DPP4 inhibition on NPY-induced peripheral vasoconstriction seems to require the context of disruption of the renin-angiotensin system. Several limitations warrant mention. As previously discussed, we found a carryover effect of exogenous NPY on FBF during infusion of enalaprilat in the healthy subjects who completed Protocol 1. This led to lower FBF before the second infusion of NPY compared with baseline. The carryover effect was similar in subjects who received sitagliptin or placebo, however, and we addressed the carryover by completing separate analyses of the effect of sitagliptin before and after enalaprilat. The study may have been underpowered to evaluate the full effect of DPP4 and ACE inhibition on sympathetic activation. Another study (URL: http:// www.clinicaltrials.gov. Unique identifier: NCT02130687) is evaluating the effects of DPP4 inhibition on norepinephrine concentrations in patients receiving chronic ACE inhibition, angiotensin receptor blockade, or calcium channel blockade. In addition, we studied the effects of sitagliptin on the vasoconstrictor response to exogenous NPY. The effects of sitagliptin on endogenous NPY may differ, but we did find that basal NPY and the ratio of NPY to NPY (3-36) were increased by sitagliptin during enalaprilat.
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Perspectives
We demonstrate for the first time an interactive effect of DPP4 inhibition and drugs that interrupt the renin-angiotensinaldosterone system on NPY-induced vasoconstriction in humans. We also demonstrate for the first time that DPP4 inhibition blocks the degradation of the Y1 agonist NPY to its Y2 agonist metabolite NPY . These findings expand on the results of previous studies, in which DPP4 inhibition prevents the antihypertensive effect of acute full-dose ACE inhibition and increases HR and circulating norepinephrine, 7, 8 suggesting DPP4 inhibition may negate the beneficial cardiovascular effects of drugs that interrupt the renin-angiotensin-aldosterone system. Defining the mechanisms of the cardiovascular effects of DPP4 inhibition, particularly in the setting of ACE inhibition or angiotensin receptor blockade, could affect the care of millions of patients with T2DM taking these drugs together. Future studies in rodent models may elucidate downstream mechanisms of potentiation of NPY, such as increased signaling through Ca2 + /calmodulin-dependent kinase II. 27 Future human studies should elucidate the effect of these drug combinations on the effects of endogenous NPY, particularly in patients with hypertension and those at risk for heart failure.
